Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer

Tanei, Tomonori; Shimomura, Atsushi; Shimazu, Kenzo; Nakayama, Takahiro; Kim, S.J.; Iwamoto, Takashi; Tamaki, Yasuhiro; Noguchi, Shinzaburo

doi:10.1016/j.ejso.2010.10.009

Cited by 61 publications

(46 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies demonstrated an association between higher Ki67 levels and Her2 positivity (Bottini et al, 2001;Viale et al, 2008;Faratian et al, 2009;Klintman et al, 2010). In contrast, Some authors reported that there was not any significant association between Ki67 levels and Her2 status (Tanei et al, 2011;Gudlaugsson et al, 2013). We also evaluated the relationship between Ki67 expression levels and Her2 status in this study, and found that Ki67 expression was higher in Her2 positive patients.…”

Section: Discussionmentioning

confidence: 97%

“…However, the reports demonstrating the relationship between Ki67 expression and tumor grade in breast cancer has been inconsistent. While many studies suggested that higher Ki67 levels were positively correlated with high grade tumors (Gasparini et al, 1991; Sahin et al, 1991;Klintman et al, 2010), others could not detect any association (Jalava et al, 2006;Faratian et al, 2009;Tanei et al, 2011). Tan et al showed that histological grade in breast cancers was significantly correlated with Ki67 immunohistochemical staining (Tan et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…The half-life of the Ki67 antigen is 1-1.5 hours (Heidebrecht et al, 1996). Although some authors suggested that high levels of Ki67 were associated with unfavorable prognosis, the prognostic and predictive value of Ki67 expression level is yet unclear in breast cancer (DeCensi et al, 2011;Tanei et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer

Kılıçkap¹,

Kaya²,

Yücel³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The prognostic value of the Ki67 expression level is yet unclear in breast cancer. The aim of this study was to investigate the association between Ki67 expression levels and prognostic factors such as grade, Her2 and hormone receptor expression status in breast cancers. Materials and Methods: Clinical and pathological features of the patients with breast cancer were retreived from the hospital records. Results: In this study, 163 patients with breast cancer were analyzed, with a mean age of 53.4±12.2 years. Median Ki67 positivity was 20% and Ki67-high tumors were significantly associated with high grade (p<0.001), lymphovascular invasion (p=0.001), estrogen receptor (ER) negativity (p=0.035), Her2 positivity (p=0.001), advanced stage (p<0.001) and lymph node positivity (p<0.003) . Lower Ki67 levels were significantly associated with longer median relapse-free and overall survival compared to those of higher Ki67 levels. Conclusions: High Ki67 expression is associated with ER negativity, Her2 positivity, higher grade and axillary lymph node involvement in breast cancers. The level of Ki67 expression is a prognostic factor predicting relapse-free and overall survival in breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer

Kılıçkap¹,

Kaya²,

Yücel³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…31,32 Some studies have determined that high expression of Ki-67 before therapy is significantly predictive, [33][34][35][36][37] but others have concluded that Ki-67 was not an independent predictor of pCR. [38][39][40] This variability in predictive value may be due to the absence of standardized, objective, and controlled methods for measurement.…”

mentioning

confidence: 99%

Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer

Brown

DiGiovanna

Killelea

et al. 2014

Laboratory Investigation

View full text Add to dashboard Cite

Measurement of Ki-67, a marker of cell proliferation, has been associated with response to therapy, but methods of measurement are controversial. Here we use a quantitative objective measurement for Ki-67 to determine the best method for assessment of Ki-67 for prediction of response to neoadjuvant chemotherapy. Analysis was conducted on a cohort of 105 consecutive invasive breast cancer patients that received neoadjuvant therapy between 2002 and 2010, and on whom pre-surgical biopsies were obtainable. Ki-67 expression was measured using quantitative immunofluorescence automated quantitative analysis (AQUA) technology. Images for each specimen were collected for 5 to 115 fields of view (FOVs) and summary scores were obtained, corresponding to the average and maximum of all the FOVs. AQUA scoring (using both intensity and area) was comparable to automated calculation of percentage of positive nuclei for prediction of response to chemotherapy (OR: 2.832 vs 2.712). Both the average and maximum AQUA score showed Ki-67 expression was directly correlated to pathological complete response (pCR; average P ¼ 0.0002; maximum P ¼ 0.0011). Although examining the maximum FOV was more predictive of response to therapy (OR: 3.546 vs 2.832), averaging all fields provided more sensitivity and specificity (AUC 0.769 vs 0.732). Ki-67 average (P ¼ 0.0025) and maximum (P ¼ 0.0239) AQUA score were also significant predictors of pCR in a multivariable analysis, including tumor size, nuclear grade, nodal status, ER status, and HER2 status. Measurement of Ki-67 expression by objective quantitative methods shows increased Ki-67 levels are an independent predictor of response to neoadjuvant chemotherapy.

show abstract

“…6. The expression of MKI67 gene after neoadjuvant chemotherapy is prognostic of disease relapse and death (von Minckwitz et al, 2013;Tanei et al, 2011). 7.…”

Section: Notementioning

confidence: 99%

MKI67 (marker of proliferation Ki-67)

Ntzeros¹,

Philip²,

Mazis³

et al. 2015

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

show abstract

Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer

Cited by 61 publications

References 23 publications

Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer

Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer

Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer

MKI67 (marker of proliferation Ki-67)

Contact Info

Product

Resources

About